Efficient Data Gathering and Aggregation for Multiple Applications in Wireless Sensor Networks

Data aggregation in wireless sensor networks refers to acquiring the sensed data from the sensors to the gateway node. It reduces the amount of power consumed during data transmission between the sensor nodes. Generally homomorphic encryptions have been applied to conceal communication during aggregation. Since enciphered data can be aggregated algebraically without decryption. Here adversaries are able to forge aggregated results by compromising them. However, these schemes are not satisfying multi-application environments, provide insecure transmission and do not provide secure counting for unauthorized aggregation attacks. In this paper, we propose a new concealed data aggregation scheme extended from homomorphic privacy encryption system. The proposed scheme designed for a multi-application environment, mitigates the impact of compromising attacks in single application environments and also it can avoid the damage from unauthorized aggregations by the privacy homomorphic encryption scheme.Comment: 14 pages, 4 figure

2-Phenyl-8,9,10,11-tetra­hydro-1-benzo­thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine

In the title compound, C17H14N4S, the benzothieno moiety is fused at one end of the pyramidine ring while the triazole ring with a phenyl substituent is fused at the other side. The triazole ring is almost planar [maximum deviation = 0.0028 (3) Å] while the cyclo­hexane ring adopts a half-chair conformation. In the crystal, pairs of inter­molecular C—H⋯N hydrogen bonds form centrosymmetric head-to-head dimers, corresponding to an R 2 2(8) graph-set motif. Further C—H⋯N inter­actions generate a zigzag chain of mol­ecules along the c axis. The supra­molecular assembly is consolidated by π–π stacking inter­actions [centroid–centroid distance = 3.445 (4) Å]

Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19

Funder: Addenbrooke's Charitable Trust, Cambridge University Hospitals; FundRef: http://dx.doi.org/10.13039/501100002927Funder: National Institute for Health Research; FundRef: http://dx.doi.org/10.13039/501100000272Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs) from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020. About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with COVID-19 during the ongoing UK ‘lockdown’. These data demonstrate how infection prevention and control measures including staff testing may help prevent hospitals from becoming independent ‘hubs’ of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions, organizations in other sectors may be able to resume on-site work safely

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

A pattern mixture model with long short-term memory network for acute kidney injury prediction

Acute kidney disease is a serious complication characterized by poor short- and long-term outcomes in the intensive care unit. Impairment in renal function of the kidney significantly increases the mortality rate. Early detection of acute kidney disease could lead to preventive interventions, therefore deep learning systems can detect it before its symptoms and consequences appear. We developed a novel deep learning architecture like Stacked long short-term memory network with pattern mixture approach for kidney injury prediction. A total of 33,754 patients encountered were retrospectively analyzed from the MIMIC-III database. A selection and pattern mixture model was used for preprocessing the time-series data. We compared the proposed result with conventional algorithms like gradient boosted trees and long short-term memory model. Our model was trained on patient time-series data for different time windows and obtained the highest accuracy of 92.4% for 12 h and 92.6% for 24 h. A novel stacked long short-term memory model outperforms the machine learning model, revealing superior performance in predicting kidney injury 24 h before onset

2-[4-(Trifluoromethoxy)phenyl]-1H-benzimidazole

In the title compound, C14H9F3N2O, the best planes of the benzimidazole group and benzene ring form a dihedral angle of 26.68 (3)°. In the crystal, N—H...N hydrogen bonds link the molecules into infinite chains parallel to the c axis. Stacking interactions between the benzimidazole groups [centroid–centroid distance = 3.594 (5) Å] assemble the molecules into layers parallel to (100). The trifluoromethyl group is disordered over three sets of sites with site-occupancy factors of 0.787 (4), 0.107 (7) and 0.106 (7)

2-(3,4-Difluorophenyl)-1H-benzimidazole

In the title molecule, C13H8F2N2, the dihedral angle between the benzimidazole ring system and the difluoro-substituted benzene ring is 30.0 (1)°. In the crystal, molecules are linked by N—H...N hydrogen bonds, forming chains along [010]. In addition, weak C—H...F hydrogen bonds connect chains into a two-dimensional network parallel to (001). A weak C—H...π interaction is observed between an H atom of the benzimidazole ring sytem and the π system of the difluoro-substituted benzene ring

2-Amino-4-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonitrile

In the title compound, C10H12N2S, the thiophene ring is essentially planar (r.m.s. deviation = 0.0290 Å). The two C atoms of the cyclohexene ring (at positions 6 and 7) are disordered over two sets of sites in a 0.810 (5):0.190 (5) ratio. The cyclohexene rings in both the major and minor occupancy conformers adopt a half-chair conformation. In the crystal, there are two types of N—H...N interaction. One of these results in centrosymmetric head-to-head dimers corresponding to an R22(12) graph-set motif and the other forms a 20-membered macrocyclic ring involving six molecules